Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Journal of Pharmacology and PharmacotherapeuticsNOW IN
    Review

    Oliceridine - Breakthrough in the Management of Pain

    Dhivya Elango1★, Divyashanthi Chellathambi Malathi1, Priyadharsini Raman Palanisamy1★ Corresponding author

    1. 1Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, (JIPMER), Karaikal, Puducherry, India.

    CORRESPONDENCE

    Dhivya Elango

    Department of Pharmacology, Jawaharlal Institute of Postgraduate Medical Education and Research, (JIPMER), Karaikal, Puducherry - 609 602, India.

    dhivya.tvmc2008@gmail.com

    Received: 28-08-2021; Revised: 19-10-2021; Accepted: 29-10-2021.

    Volume 12, Issue 4 · pp. 157–162 · PUBLISHED 9 February 2022 · DOI: 10.4103/jpp.jpp_116_21

    View on J Pharmacol. Pharmacother. original site ↗

    ABSTRACT

    Oliceridine an intravenous opioid approved in 2020 by the Food and Drug Administration (FDA) to treat moderate-to-severe pain. Oliceridine developed with a novel mechanism that is biased agonism toward G-protein-coupled receptors pathway. Being biased agonist, it does not activate beta arrestin pathway responsible for opioid-related adverse events (ORAE), especially respiratory depression. Because of the novel mechanism, oliceridine has paved a pathway to decrease ORAE. Oliceridine has received breakthrough status by FDA. However, FDA denied oliceridine approval and withdrew breakthrough status by 2019. FDA made this decision because of the inadequacy of the safety data. Abuse potential and QT prolongation studies are conducted as per FDA recommendation in the year 2019; oliceridine was approved for moderate to severe pain in adults. This review will briefly summarize the pharmacological properties and study results of oliceridine in the management of pain. Thorough literature search was done for the efficacy and safety of oliceridine, search was done in electronic database of PubMed and Cochrane from inception till June 2021. Oliceridine was found to be effective in acute severe pain with less OREA when compared to morphine. Oliceridine has many drawbacks than what is hypothesized earlier, but this approach has opened new options for patients suffering from severe pain. Long-term effect of oliceridine has to be monitored to assess the effects of biased agonism.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Elango, D., Malathi, D. C., & Palanisamy, P. R. (2022). Oliceridine - Breakthrough in the Management of Pain. Journal of Pharmacology and Pharmacotherapeutics, 12(4), 157–162. https://doi.org/10.4103/jpp.jpp_116_21